Iovance Biotherapeutics, Inc. Common Stock Earnings Dividend

Iovance Biotherapeutics, Inc. Common Stock’s revenue jumped 65.65% since last year same period to $99.31Mn in the Q2 2026. On a quarterly growth basis, Iovance Biotherapeutics, Inc. Common Stock has generated 39.04% jump in its revenue since last 3-months.

Iovance Biotherapeutics, Inc. Common Stock’s net profit jumped 57.63% since last year same period to $-47.32Mn in the Q2 2026. On a quarterly growth basis, Iovance Biotherapeutics, Inc. Common Stock has generated 40.14% jump in its net profits since last 3-months.

Iovance Biotherapeutics, Inc. Common Stock’s net profit margin jumped 74.42% since last year same period to -47.64% in the Q2 2026. On a quarterly growth basis, Iovance Biotherapeutics, Inc. Common Stock has generated 56.95% jump in its net profit margins since last 3-months.

Iovance Biotherapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.17 - a -10.75% fall from last quarter’s estimates.

Iovance Biotherapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.17.

Iovance Biotherapeutics, Inc. Common Stock’s earning per share (EPS) jumped 66.67% since last year same period to -0.11 in the Q2 2026. This indicates that the Iovance Biotherapeutics, Inc. Common Stock has generated 66.67% annual rate of jump in its earning per share (EPS) in the last 4 quarters.